EUVIMEDOpdag EUVIMED
Crossref

Phase 1 trial suggests benefit of psilocybin in OCD treatment

The Brown University Psychopharmacology Update · 2026-08 · 37 (8) · 3-4

DOI: 10.1002/pu.31474 ↗

At a glance

Journal article in The Brown University Psychopharmacology Update, published online on 2026-06-28.

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

A Phase 1 trial comprising 15 patients has found that repeated high‐dose administration of psilocybin was more effective than low‐dose psilocybin or placebo in reducing symptoms of obsessive‐compulsive disorder (OCD). Psilocybin was generally well‐tolerated, with no reports of serious adverse events.

Cite

APA

(2026). Phase 1 trial suggests benefit of psilocybin in OCD treatment. The Brown University Psychopharmacology Update, 37(8), 3-4. https://doi.org/10.1002/pu.31474

Vancouver

Phase 1 trial suggests benefit of psilocybin in OCD treatment. The Brown University Psychopharmacology Update. 2026;37(8):3-4. doi:10.1002/pu.31474

BibTeX
@article{euvimed2026,
  title = {Phase 1 trial suggests benefit of psilocybin in OCD treatment},
  journal = {The Brown University Psychopharmacology Update},
  year = {2026},
  volume = {37},
  number = {8},
  pages = {3--4},
  doi = {10.1002/pu.31474}
}
Start for free →